aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
15. November 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
07. November 2024 16:01 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
aTyr Pharma to Present at Upcoming Investor Conferences
31. Oktober 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to present at upcoming investor conferences
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
08. Oktober 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
02. Oktober 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
aTyr Pharma to Participate in September Investor Conferences
21. August 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Participate in September Investor Conferences
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
13. August 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
06. August 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
aTyr Pharma Announces Research Study with Stanford Medicine
30. Juli 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03. Juni 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”